0001209191-20-042498.txt : 20200715 0001209191-20-042498.hdr.sgml : 20200715 20200715170011 ACCESSION NUMBER: 0001209191-20-042498 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200714 FILED AS OF DATE: 20200715 DATE AS OF CHANGE: 20200715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hirsch David CENTRAL INDEX KEY: 0001619884 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 201030014 MAIL ADDRESS: STREET 1: C/O LONGITUDE CAPITAL PARTNERS, LLC STREET 2: 800 EL CAMINO REAL, SUITE 220 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-14 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001619884 Hirsch David C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121 1 0 0 0 Common Stock 2020-07-14 4 C 0 2464245 A 2464245 I See footnote Common Stock 2020-07-14 4 P 0 250000 16.00 A 2714245 I See footnote Series B Preferred Stock 2020-07-14 4 C 0 2581755 D Common Stock 2070373 0 I See footnote Series C Preferred Stock 2020-07-14 4 C 0 491159 D Common Stock 393872 0 I See footnote Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Represents shares held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power over securities held by LVP III. The reporting person is a member of LCP III and may be deemed to share voting, investment and dispositive power with respect to securities held by LVP III. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. /s/ Johanna M. Mylet, Attorney-in-Fact 2020-07-15